SAR164877: Additional Phase II data

Additional data from the double-blind, U.S. Phase II Study 0901 trial in 217 patients showed that the 0.1 and 0.3 mg/kg doses of IV REGN475 significantly reduced mean NRS walking pain

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE